Order Article Reprints

Manji A, Samson Y, Deyell RJ, Johnston DL, Lewis VA, Zorzi AP, Berman JN, Brodeur-Robb K, Morrison E, Kee L, et al. Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial. Cancers. 2022; 14(12):2985. https://doi.org/10.3390/cancers14122985

Manji, Arif, Yvan Samson, Rebecca J. Deyell, Donna L. Johnston, Victor A. Lewis, Alexandra P. Zorzi, Jason N. Berman, Kathy Brodeur-Robb, Ellen Morrison, Lynn Kee, and et al. 2022. "Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial" Cancers 14, no. 12: 2985. https://doi.org/10.3390/cancers14122985

Manji, A., Samson, Y., Deyell, R. J., Johnston, D. L., Lewis, V. A., Zorzi, A. P., Berman, J. N., Brodeur-Robb, K., Morrison, E., Kee, L., Kumar, S., Baruchel, S., Whitlock, J. A., & Morgenstern, D. A. (2022). Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial. Cancers, 14(12), 2985. https://doi.org/10.3390/cancers14122985